Clinical Trials Browser

Phase 3 × Not yet recruiting × selinexor × Clear all

NCT06613035 2024-09-25

Twice-per-weekSelinexor, 2 Days Melphalan

Phase 3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute